 |
|
|
| |
Adverse birth outcomes and risk of MTCT for dolutegravir versus efavirenz in 5 randomised trials of 1074 pregnant women
|
| |
| |
Glasgow HIV 2022 Oct 23-26
Simiso Sokhela1, Francois Venter1, Bronwyn Bosch1, Godspower Akpomiemie1, Angela Tembo1, Toby Pepperrell2, Bryony Simmons3, Lloyd B. Mulenga4, Alexandra Calmy5, Tamara Tovar
Sanchez6, Eric Delaporte6, Charles Kouanfack7, Mireille Mpoudi-Etame8, Carmen Perez Casas9, Saye Khoo10, Helen Reynolds10, Andrew Hill10
1.University of the Witwatersrand Faculty of Health Sciences, Johannesburg, South Africa 2.University of Edinburgh, School of Medicine and Veterinary Medicine, Edinburgh, UK 3.London School of Economics and Political Science, LSE Health, London, UK 4.University Teaching Hospital, Lusaka, Zambia 5.Genva University Hospitals, Division of Infectious Diseases, HIV-AIDS Unit, Geneva, Switzerland 6.University of Montpellier, TransVIHMI, Montpellier, France 7.Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Dschang, Cameroon; Day Stay Hospital, Central Hospital of Yaoundé, Henri-Dunant, Yaoundé, Cameroon; ANRS Cameroon site, Central Hospital of Yaoundé, Henri-Dunant, Yaoundé, Cameroon 8.Regional Military Hospital Number 1, Yaoundé, Cameroon 9.Unitaid, Global Health Campus, Le Grand-Saconnex, Switzerland 10.University of Liverpool, Department of Pharmacology and Therapeutics, Liverpool, UK
|
| |
|
|
|
|
|
